Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495873 | 0.93 | GRM2 (0.48) | GRM2KDM1AALDH1A1MAPTCYP2C9 | |
| SCHEMBL3138790 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL3148352 | 0.81 | ALOX15 (0.43) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL1495871 | 0.80 | GRM2 (0.57) | GRM2KDM1AALDH1A1MAPTCYP2C9 | |
| SCHEMBL3144469 | 0.76 | RAB9A (0.42) | GRM2ALDH1A1 | |
| SCHEMBL1495907 | 0.73 | GRM2 (0.50) | GRM2KDM1AALDH1A1MAPTCYP2C9 | |
| SCHEMBL1495909 | 0.73 | GRM2 (0.50) | GRM2KDM1AALDH1A1MAPTCYP2C9 | |
| SCHEMBL3135569 | 0.73 | PARP15 (0.40) | GRM2MAPT | |
| SCHEMBL1516010 | 0.73 | GRM2 (0.33) | GRM2ALDH1A1MAPTBACE1 | |
| SCHEMBL3148324 | 0.73 | DRD4 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051331-B2 | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2015-06-09 | — | — | US | disclosed |
| EP-2477994-B1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-12-11 | — | — | EP | disclosed |
| EP-2477994-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| WO-2011034830-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | GRM2 1/4885KDM1A 1151/4885ALDH1A1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.